ScreenerHero

AARD Aardvark Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · aardvarktherapeutics.com
4.710USD-5.04%Mkt Cap: 103.08M $P/E: —

Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therape…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.47BUSDP/E 29.3
MRNA
Moderna, Inc.
$78.65BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.14BUSDP/E 18.3
ARGX
argenx SE
$51.48BUSDP/E 31.2
ARGX
argenx SE
$48.23BUSDP/E 31.4
UCB
UCB SA
$41.82BUSDP/E 17.8
RVMD
Revolution Medicines, Inc.
$40.32BUSD
ONC
BeOne Medicines AG
$39.83BUSDP/E 62.6
RPRX
Royalty Pharma plc
$32.48BUSDP/E 29.9
ALNY
Alnylam Pharmaceuticals, Inc.
$30.04BUSDP/E 37.9
ROIV
Roivant Sciences Ltd.
$24.71BUSD
BNTX
BioNTech SE
$23.13BUSD
INCY
Incyte Corporation
$22.85BUSDP/E 14.4
GMAB
Genmab A/S
$22.17BUSDP/E 28.4
INSM
Insmed Incorporated
$21.94BUSD
GMAB
Genmab A/S
$21.10BUSDP/E 29.1
ASND
Ascendis Pharma A/S
$14.65BUSDP/E 17.1
EXEL
Exelixis, Inc.
$14.62BUSDP/E 18.6
JAZZ
Jazz Pharmaceuticals plc
$14.44BUSDP/E 15.2
SMMT
Summit Therapeutics Inc.
$13.70BUSD

Key Statistics

Company
Market Cap103.08M USD
Enterprise Value37.11M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-57.59M USD
Revenue/Share—
Last Price4.710 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees28
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.12
PEG—
EV/EBITDA-0.50
EV/Revenue—
P/S—
P/B1.47
EPS (TTM)-3.10
EPS (Forward)-2.38
52W Range
3.3509% of range17.94
52W High17.94 USD
52W Low3.350 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-54.01%
ROA-49.15%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-54.17M USD
CapEx (TTM)95.00K USD
FCF Margin—
FCF Yield-45.50%
Net Debt-73.19M USD
Net Debt/EBITDA0.99
Balance Sheet
Debt/Equity0.00
Current Ratio12.63
Quick Ratio11.57
Book Value/Sh3.42 USD
Cash/Share3.38 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.3 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)11.11 USD
Upside (mean)+135.9%
Target Range3.000 USD – 28.00 USD
3.000+135.9% to mean28.00
# Analysts9
Ownership
Shares Out.21.88M
Float11.01M
Insiders15.77%
Institutions52.61%
Short Interest
Short Ratio2.9d
Short % Float2.90%
Short % Out.1.94%
Shares Short424.91K
Short (prev mo.)611.76K
Technical
SMA 506.068 (-22.4%)
SMA 2007.326 (-35.7%)
Beta—
S&P 52W Chg16.45%
Avg Vol (30d)128.13K
Avg Vol (10d)70.88K
Technical Indicators
RSI (14)38.3
MACD-0.2454
MACD Signal-0.2242
MACD Hist.-0.0212
BB Upper5.796 USD
BB Middle5.266 USD
BB Lower4.737 USD
BB Width20.10%
ATR (14)0.5443 USD
Vol Ratio (20d)2.61x